Shares in Telix Pharmaceuticals have surged more than tenfold in five years as a record June quarter of sales supports phenomenal investor interest in the cancer diagnostic and treatment business.
Antares is among Australian equities managers such as Platinum Asset Management, Perennial Partners, Fidelity, Acorn Capital, and Wilson Asset Management that own Telix shares. “We still think shares have further upside,” said Mr Hamilton. “I think that first [June] quarter of commercial sales in Illucix show it’s a great product. It entered the market and got very good awareness of PSMA imaging.
tommyr345 still a puppet for asxlongtail Only biotech Tom covers strangely, share price is the same as last time you wrote a puff piece for him 🤡
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: